Jeffrey E. Lancet, MD, chair of the Department of Malignant Hematology at Moffitt Cancer Center, gave insight on the evolving treatment landscape of acute myeloid leukemia (AML) and the potential of immunotherapy and targeted therapies going forward.
Jeffrey E. Lancet, MD, chair of the Department of Malignant Hematology at Moffitt Cancer Center, gave insight on the evolving treatment landscape of acute myeloid leukemia (AML) and the potential of immunotherapy and targeted therapies going forward.
Transcript
How do you expect the AML treatment landscape to evolve going forward, and how might new developments impact the current treatment paradigm?
I think the field is evolving gradually, as we understand the most important molecular genetic changes that are associated with the disease and which mutations, for example, need to be targeted at various time points. That understanding, along with the development of new drugs that target these genetic abnormalities, I think are going to drive the progress of the disease.
And right now, unfortunately, we have a lot of targets, potentially, but we don't have a lot of drugs. So the development of drugs lags behind the knowledge about the targets. But I do see more targeted therapy evolving over time. And I think there's also going to be an important role for immunotherapy, which could be considered a form of targeted therapy, but probably not to the same degree, because you're really trying to harness the immune system in a way that recognizes the leukemia cells as being foreign and attacking and destroying them. And that can be done through a variety of methods, including antibody-based therapies, what we call bispecific antibodies, in some cases where you target the leukemia cell and put it in proximity to a T cell that can kill it by bringing the cells close together.
Then, of course, you have the whole field of cellular immunotherapy, which involves options such as CAR-T therapy, which are really still in the very early stages and not yet standard of care. But these types of therapies certainly will be expensive, and probably change the financial landscape of how we treat this disease, as well. But right now, we're not yet at a point where we have clearly defined standard-of-care types of effective therapies in the immunotherapy realm, for the most part, in AML. But I think it's coming, and I think we have to be ready to tackle the questions about which patients should be receiving it so that we're not treating some patients unnecessarily, and how long people should be on it. You know, what are the risks associated with drugs such as immunotherapies that may help people live longer but have more chronic toxicities that have to be dealt with? [Another factor is] the overall cost of care in an already very expensive-to-treat disease.
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Males With Hemophilia A Report Physical, Mental Burdens of Disease Regardless of Severity
April 25th 2024Self-reported data from adult and pediatric males with hemophilia A show that burden of the disease persists regardless of severity, highlighting a need for improved prophylactic treatment.
Read More
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
What We’re Reading: FDA Approves UTI Antibiotic; Ozempic, Wegovy Price Investigation; US Births Fall
April 25th 2024The FDA recently approved an antibiotic for the treatment of urinary tract infections (UTIs) in women; a Senate committee recently launched an investigation into the prices of Novo Nordisk’s diabetes and weight loss drugs; US births fell last year, resuming a national slide after a previous increase during the pandemic.
Read More
HOPE-CAT Can Identify Maternal Cardiovascular Risk 2 Months Earlier Than Doctors, Study Says
April 25th 2024In a retrospective study, the machine learning tool was able to screen for potential risks of cardiovascular disease nearly 60 days before the patient's medical record showed any signs of a related condition or before they were officially diagnosed or treated for it.
Read More